Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Apatinib, and Nab-paclitaxel in Locally Advanced Gastric Cancer
NCT05524974Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib, paclitaxel in gastric cancer (GC), sponsored by Fujian Medical University. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05524974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524974.